JP2006506381A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006506381A5 JP2006506381A5 JP2004546433A JP2004546433A JP2006506381A5 JP 2006506381 A5 JP2006506381 A5 JP 2006506381A5 JP 2004546433 A JP2004546433 A JP 2004546433A JP 2004546433 A JP2004546433 A JP 2004546433A JP 2006506381 A5 JP2006506381 A5 JP 2006506381A5
- Authority
- JP
- Japan
- Prior art keywords
- prostaglandin
- compound
- composition
- dihydro
- prostaglandin compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 prostaglandin compound Chemical class 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000004423 acyloxy group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42033602P | 2002-10-23 | 2002-10-23 | |
| US60/420,336 | 2002-10-23 | ||
| PCT/JP2003/013453 WO2004037268A1 (en) | 2002-10-23 | 2003-10-22 | Prostaglandin compounds for the treatment of obesity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006506381A JP2006506381A (ja) | 2006-02-23 |
| JP2006506381A5 true JP2006506381A5 (enExample) | 2006-12-07 |
| JP4705782B2 JP4705782B2 (ja) | 2011-06-22 |
Family
ID=32176556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004546433A Expired - Fee Related JP4705782B2 (ja) | 2002-10-23 | 2003-10-22 | 肥満の処置のためのプロスタグランジン化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8114911B2 (enExample) |
| EP (1) | EP1562604B1 (enExample) |
| JP (1) | JP4705782B2 (enExample) |
| AT (1) | ATE539756T1 (enExample) |
| AU (1) | AU2003274735B2 (enExample) |
| CA (1) | CA2502439C (enExample) |
| DK (1) | DK1562604T3 (enExample) |
| ES (1) | ES2379652T3 (enExample) |
| NZ (1) | NZ539582A (enExample) |
| PT (1) | PT1562604E (enExample) |
| WO (1) | WO2004037268A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8337891B2 (en) | 2003-07-03 | 2012-12-25 | Sucampo Ag | Enteric coated composition comprising prostaglandin analogs as chloride channel opener |
| US7666912B2 (en) | 2006-03-23 | 2010-02-23 | Massachusetts Eye And Ear Infirmary | Compositions and methods for reducing body fat |
| CA2824317C (en) | 2011-01-19 | 2014-12-16 | Terakine Therapeutics, Inc. | Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia |
| US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
| KR101651448B1 (ko) | 2012-11-21 | 2016-08-26 | 토포카인 쎄라퓨틱스, 인코포레이티드 | 체지방을 국소적으로 증가시키는 방법 및 조성물 |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| US20140308354A1 (en) | 2013-04-12 | 2014-10-16 | Allergan, Inc. | Sustained release bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction |
| NO2753788T3 (enExample) | 2013-05-10 | 2018-06-16 | ||
| WO2014186504A1 (en) | 2013-05-15 | 2014-11-20 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
| US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
| US11452703B2 (en) | 2020-05-21 | 2022-09-27 | Peregrine Ophthalmic PTE LTD. | Methods and compositions for reducing adipocyte numbers |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US388919A (en) * | 1888-09-04 | Benjamin scables | ||
| US3888919A (en) * | 1971-03-11 | 1975-06-10 | Upjohn Co | 11,15 dimethyl pge' 1 'and pgf' 1' |
| US5166174A (en) * | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| CA1322749C (en) * | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
| US5221763A (en) * | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| US5317032A (en) * | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
| JP2597629B2 (ja) * | 1988-02-26 | 1997-04-09 | 株式会社 上野製薬応用研究所 | １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化 |
| NZ226198A (en) * | 1988-09-15 | 1991-05-28 | Ueno Seiyaku Oyo Kenkyujo Kk | Fervescence (temperature raising) composition comprising 15-keto-pge |
| NZ226199A (en) * | 1988-09-15 | 1991-05-28 | Ueno Seiyaku Oyo Kenkyujo Kk | 13,14-dihydro-15-keto-pgf derivatives and pharmaceutical compositions |
| DE69006964T2 (de) * | 1989-07-27 | 1994-06-09 | Ueno Seiyaku Oyo Kenkyujo Kk | Behandlung von Hyperlipidemia mit 15-keto-Prostaglandin-Verbindungen. |
| US5234954A (en) * | 1989-07-27 | 1993-08-10 | K.K. Ueno Seiyaku Oyo Kenkyujo | Treatment of hyperlipidemia with 15-keto-prostaglandin compounds |
| JPH085794B2 (ja) * | 1989-07-27 | 1996-01-24 | 株式会社上野製薬応用研究所 | 高脂質血症処置・血中脂質成分低下剤 |
| TW224942B (enExample) * | 1990-04-04 | 1994-06-11 | Adka Ueno Kk | |
| CA2150287C (en) * | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| US6022897A (en) * | 1995-04-25 | 2000-02-08 | The Salk Institute For Biological Studies | Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
| US6242485B1 (en) * | 1996-06-10 | 2001-06-05 | R-Tech Ueno | Endothelin antagonist |
| EP1071429B1 (en) * | 1998-04-17 | 2002-01-30 | Trustees Of Tufts College | Map kinase inhibitors in the treatment of disorders caused by tnf-alpha induced lipolysis |
| JP2000157260A (ja) * | 1998-11-26 | 2000-06-13 | Toyobo Co Ltd | 初代前駆脂肪細胞の分化誘導方法及びその分化用培地 |
| DE60039727D1 (de) * | 1999-10-15 | 2008-09-11 | Sucampo Ag | Neue Zusammensetzung enthaltend eine bicyclische Verbindung und ein Glycerid |
| US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
| TWI302100B (en) * | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
| AR035242A1 (es) * | 2001-05-18 | 2004-05-05 | Sucampo Ag | Uso de un lipido bioactivo halogenadopara preparar una composicion catartica y compuesto lipido bioactivo halogenado |
| AU2002330747B2 (en) * | 2001-08-31 | 2007-07-19 | Sucampo Ag | Prostaglandin analogs as chloride channel opener |
| TWI331920B (en) * | 2001-11-14 | 2010-10-21 | Sucampo Ag | Unit dosage form for relieving or treating constipation in human patients |
| US7732487B2 (en) * | 2001-11-19 | 2010-06-08 | Sucampo Ag | Method for treating a disease or condition responsive to opening of C1C-2 channel |
| AU2003292556B2 (en) * | 2002-12-27 | 2009-09-10 | Sucampo Ag | Derivatives of prostaglandins for treating abdominal discomfort |
| US8337891B2 (en) * | 2003-07-03 | 2012-12-25 | Sucampo Ag | Enteric coated composition comprising prostaglandin analogs as chloride channel opener |
| TWI387454B (zh) * | 2004-09-02 | 2013-03-01 | 蘇坎波公司 | 治療胃腸道疾病之方法及組成物 |
| US20060281818A1 (en) * | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| EP1871380B1 (en) * | 2005-04-12 | 2011-10-19 | Sucampo AG | Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders |
-
2003
- 2003-10-22 EP EP03758747A patent/EP1562604B1/en not_active Expired - Lifetime
- 2003-10-22 DK DK03758747.4T patent/DK1562604T3/da active
- 2003-10-22 ES ES03758747T patent/ES2379652T3/es not_active Expired - Lifetime
- 2003-10-22 JP JP2004546433A patent/JP4705782B2/ja not_active Expired - Fee Related
- 2003-10-22 NZ NZ539582A patent/NZ539582A/en not_active IP Right Cessation
- 2003-10-22 AU AU2003274735A patent/AU2003274735B2/en not_active Ceased
- 2003-10-22 AT AT03758747T patent/ATE539756T1/de active
- 2003-10-22 WO PCT/JP2003/013453 patent/WO2004037268A1/en not_active Ceased
- 2003-10-22 US US10/531,874 patent/US8114911B2/en not_active Expired - Fee Related
- 2003-10-22 PT PT03758747T patent/PT1562604E/pt unknown
- 2003-10-22 CA CA2502439A patent/CA2502439C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250099419A1 (en) | Bicyclic compound and use thereof for medical purposes | |
| JP2004527567A5 (enExample) | ||
| JP4044967B2 (ja) | １１，１５−ｏ−ジアルキルプロスタグランジンｅ誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 | |
| JP2006513232A5 (enExample) | ||
| KR100349964B1 (ko) | ω-시클로알킬 프로스타글란딘 Ｅ1 유도체 | |
| JP2005504836A5 (enExample) | ||
| JP2008531468A5 (enExample) | ||
| JP2009114217A5 (enExample) | ||
| JP2003504397A5 (enExample) | ||
| JPWO1998034916A1 (ja) | １１，１５−ｏ−ジアルキルプロスタグランジンｅ誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 | |
| JP2004507521A5 (enExample) | ||
| JP5835236B2 (ja) | 二環式化合物およびその医薬用途 | |
| JP2004502732A5 (enExample) | ||
| CA2713547A1 (en) | Biaryl amides | |
| US9150537B2 (en) | Bicyclic compound and use thereof for medical purposes | |
| JP2007517037A5 (enExample) | ||
| JP2007518685A5 (enExample) | ||
| JP2004519412A5 (enExample) | ||
| JP2010533707A5 (enExample) | ||
| JP2006518765A5 (enExample) | ||
| JP2008528440A5 (enExample) | ||
| CA2502439A1 (en) | Prostaglandin compounds for the treatment of obesity | |
| JP2004529177A5 (enExample) | ||
| JP2014237711A5 (enExample) | ||
| JP2011509237A5 (enExample) |